1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | MKN7; MKN 7 |
| Species | Human |
| Cat.No | ABC-TC0688 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Stomach |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Gastric Cancer Cell Lines |
MKN-7 is derived from well-differentiated tubular adenocarcinoma. These cells are meticulously cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, utilizing a passage method involving treatment with 0.02% EDTA and 0.25% trypsin. The CO2 concentration during cultivation is maintained at 5%, and the cells demonstrate an infinite lifespan. AcceGen uphold the highest standards for your research endeavors. The MKN-7 cell line is characterized by the amplification of the c-erbB2 oncogene and cyclin E gene, originating from a 39-year-old Asian individual with metastatic lymph nodes. These cells exhibit epithelial morphology and adhere to the culture substrate. For optimal subculturing, it is recommended to employ a split ratio ranging from 1:2 to 1:6, with subculture events occurring 2 to 3 times per week.
Why choose MKN-7 from AcceGen?
The DNA profiles of MKN-7, including D5S818, D13S317, D7S820, D16S539, vWA, TH01, Amelogenin, TPOX, and CSF1PO, are identified. Virus DNA detection reveals positive results for GAPDH and negative results for CMV, EBV, HHV6, HHV7, BKV, JCV, ADV, HBV, parvoB19, HTLV1, HTLV2, HIV1, HIV2, and HPV18.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
Gastric cancer is still a major health concern with worldwide 1,033,701 new cases and 782,685 deaths in 2018. Patients with HER2-positive recurrent or metastatic gastric cancer benefit from treatment with trastuzumab in combination with platin-fluoropyrimidine chemotherapy. Since not all patients respond or develop resistance during treatment with the HER2-antibody trastuzumab, alternative treatment options are needed. To address these challenges, AcceGen’s MKN-7 offer a valuable resource for researching and developing alternative strategies for the management of gastric cancer, particularly in the context of HER2-positive cases. The unique characteristics and properties of the MKN-7 cell line contribute to advancing the understanding of gastric cancer biology and exploring novel therapeutic interventions.
